A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

Published:2013-08-23 Issue:3 Volume:163 Page:334-342
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Coiffier Bertrand¹,Radford John²,Bosly André³,Martinelli Giovanni⁴,Barca Gabriela⁵,Davies Andrew⁶,Decaudin Didier⁷,Gallop-Evans Eve⁸,Padmanabhan-Iyer Swaminathan⁹,Van Eygen Koen¹⁰,Wu Ka Lung¹¹,Gupta Ira V.¹²,Lin Thomas S.¹²,Goldstein Nancy¹³,Jewell Roxanne C.¹³,Winter Paul¹⁴,Lisby Steen¹⁵,

Affiliation:

1. Service d'Hematologie; Hospices Civils de Lyon; Lyon; France

2. The Christie NHS Foundation Trust and The University of Manchester; Manchester; UK

3. Service d'Hématologie; Clinique Universitaires UCL de Mont-Godinne; Yvoir; Belgium

4. Divisione di Ematoncologia; Istituto Europeo di Oncologia; Milan; Italy

5. Department of Hematology; Coltea Clinical Hospital; Bucharest; Romania

6. Cancer Research UK Centre; University of Southampton; Southampton; UK

7. Departments of Medical Oncology and Translational Research; Institut Curie; Paris; France

8. Department of Clinical Oncology; Velindre Cancer Centre; Cardiff; UK

9. Institute for Drug Development; University of Texas Health Science Center at San Antonio; San Antonio; TX; USA

10. Oncologisch Centrum; AZ Groeninge; Kortrijk; Belgium

11. Department of Hematology; Ziekenhuis Stuivenberg; Antwerpen; Belgium

12. GlaxoSmithKline; Collegeville; PA; USA

13. GlaxoSmithKline; Research Triangle Park; NC; USA

14. GlaxoSmithKline; London; UK

15. Genmab; Copenhagen; Denmark

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12537/fullpdf

Reference18 articles.

1. How I treat patients with diffuse large B-cell lymphoma;Armitage;Blood,2007

2. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

3. Chemotherapy-Refractory Diffuse Large B-Cell Lymphomas (DLBCL) are effectively killed by Ofatumumab-induced complement-mediated cytoxicity;Cillessen;Blood (ASH Annual Meeting Abstracts),2007

4. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study;Coiffier;Blood,1998

5. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;New England Journal of Medicine,2002

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas;Lymphatics;2024-01-05

2. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

3. Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma;Journal of Hematology;2023-08

4. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis;Cancer Research and Treatment;2023-07-15

5. Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab;Cancers;2022-04-10